by admin | Jul 29, 2022 | Press Releases
Anaveon today announced that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, in a poster presentation at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, September 9 – 13, 2022. Abstracts will be available online starting 00.05 CEST on Monday, September 5, 2022. 
by admin | Jul 13, 2022 | Press Releases
Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions. 
by admin | Jul 13, 2022 | Press Releases
Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma. 
Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitorsNovember 1, 2023
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual MeetingOctober 16, 2023
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023